$275M Placement Closes, Two Directors to Step Down Under Succession Plan
ENTX has more than doubled off its 52-week low of $0.91.
Summary
Entera Bio closed its $275M oversubscribed private placement at $2.04/share, extending its cash runway through 2030 and funding potential EB613 commercialization. The deal was priced at a modest discount to the $2.98 market price, reflecting strong demand. In a separate development, directors Haya Taitel and Yonatan Malca will resign once new independent directors are appointed under a succession plan. The placement was previously announced on July 27, but the director departures are new. The board changes follow the placement's closing, which gave BVF Partners two board seats per the 8-K filed July 28.
At the time of this announcement, ENTX was trading at $2.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $147.4M. The 52-week trading range was $0.91 to $4.20. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.